Adalimumab Products — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Medication is prescribed by or in consultation with a rheumatologist or a dermatologist

Reauthorization criteria

• Patient has been established on therapy for at least 6 months
• Patient experienced a beneficial clinical response from baseline when assessed by at least one objective measure OR patient experienced an improvement in at least one symptom (e.g., less joint pain, morning stiffness, fatigue, improved function, or decreased swelling)

Approval duration

initial 6 months, reauth 1 year